Generic and Biosimilar Pharmaceuticals - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511244296

Publication Date:

November 4, 2024

Pages:

129

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Generic and Biosimilar Pharmaceuticals was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic and Biosimilar Pharmaceuticals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Generic and Biosimilar Pharmaceuticals by region & country, by Type, and by Application.
The Generic and Biosimilar Pharmaceuticals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic and Biosimilar Pharmaceuticals.
麻豆原创 Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Segment by Type:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Generic and Biosimilar Pharmaceuticals manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Generic and Biosimilar Pharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Generic and Biosimilar Pharmaceuticals in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Generic and Biosimilar Pharmaceuticals Product Introduction
1.2 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Size Forecast
1.3 Generic and Biosimilar Pharmaceuticals 麻豆原创 Trends & Drivers
1.3.1 Generic and Biosimilar Pharmaceuticals Industry Trends
1.3.2 Generic and Biosimilar Pharmaceuticals 麻豆原创 Drivers & Opportunity
1.3.3 Generic and Biosimilar Pharmaceuticals 麻豆原创 Challenges
1.3.4 Generic and Biosimilar Pharmaceuticals 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Generic and Biosimilar Pharmaceuticals Players Revenue Ranking (2023)
2.2 Global Generic and Biosimilar Pharmaceuticals Revenue by Company (2019-2024)
2.3 Key Companies Generic and Biosimilar Pharmaceuticals Manufacturing Base Distribution and Headquarters
2.4 Key Companies Generic and Biosimilar Pharmaceuticals Product Offered
2.5 Key Companies Time to Begin Mass Production of Generic and Biosimilar Pharmaceuticals
2.6 Generic and Biosimilar Pharmaceuticals 麻豆原创 Competitive Analysis
2.6.1 Generic and Biosimilar Pharmaceuticals 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Generic and Biosimilar Pharmaceuticals Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monoclonal Antibodies
3.1.2 Interferon
3.1.3 Erythropoietin
3.1.4 Insulin
3.1.5 Vaccines
3.1.6 Other
3.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type
3.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Type (2019-2030)
3.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Tumor
4.1.2 Diabetes
4.1.3 Cardiovascular
4.1.4 Hemophilia
4.1.5 Other
4.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application
4.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Application (2019-2030)
4.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region
5.1.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2019-2024)
5.1.3 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2025-2030)
5.1.4 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.2.2 North America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.3.2 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.4.2 Asia Pacific Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.5.2 South America Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
5.6.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Generic and Biosimilar Pharmaceuticals Sales Value
6.3 United States
6.3.1 United States Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.3.2 United States Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.4.2 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.5.2 China Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.5.3 China Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.6.2 Japan Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.7.2 South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.8.2 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Generic and Biosimilar Pharmaceuticals Sales Value, 2019-2030
6.9.2 India Generic and Biosimilar Pharmaceuticals Sales Value by Type (%), 2023 VS 2030
6.9.3 India Generic and Biosimilar Pharmaceuticals Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Amgen
7.2.1 Amgen Profile
7.2.2 Amgen Main Business
7.2.3 Amgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.2.5 Amgen Recent Developments
7.3 AbbVie
7.3.1 AbbVie Profile
7.3.2 AbbVie Main Business
7.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi-Aventis Recent Developments
7.4 Sanofi-Aventis
7.4.1 Sanofi-Aventis Profile
7.4.2 Sanofi-Aventis Main Business
7.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi-Aventis Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Profile
7.5.2 Johnson & Johnson Main Business
7.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.5.5 Johnson & Johnson Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Profile
7.7.2 Novo Nordisk Main Business
7.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.7.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.7.5 Novo Nordisk Recent Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Profile
7.8.2 Eli Lilly Main Business
7.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.8.5 Eli Lilly Recent Developments
7.9 Novartis
7.9.1 Novartis Profile
7.9.2 Novartis Main Business
7.9.3 Novartis Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.9.5 Novartis Recent Developments
7.10 Merck
7.10.1 Merck Profile
7.10.2 Merck Main Business
7.10.3 Merck Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.10.5 Merck Recent Developments
7.11 3sbio
7.11.1 3sbio Profile
7.11.2 3sbio Main Business
7.11.3 3sbio Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.11.5 3sbio Recent Developments
7.12 Changchun High Tech
7.12.1 Changchun High Tech Profile
7.12.2 Changchun High Tech Main Business
7.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.12.5 Changchun High Tech Recent Developments
7.13 CP Guojian
7.13.1 CP Guojian Profile
7.13.2 CP Guojian Main Business
7.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.13.5 CP Guojian Recent Developments
7.14 Biotech
7.14.1 Biotech Profile
7.14.2 Biotech Main Business
7.14.3 Biotech Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.14.5 Biotech Recent Developments
7.15 Gelgen
7.15.1 Gelgen Profile
7.15.2 Gelgen Main Business
7.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.15.5 Gelgen Recent Developments
7.16 Innovent
7.16.1 Innovent Profile
7.16.2 Innovent Main Business
7.16.3 Innovent Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.16.5 Innovent Recent Developments
7.17 Dong Bao
7.17.1 Dong Bao Profile
7.17.2 Dong Bao Main Business
7.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.17.5 Dong Bao Recent Developments
7.18 Ganlee
7.18.1 Ganlee Profile
7.18.2 Ganlee Main Business
7.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Products, Services and Solutions
7.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) & (2019-2024)
7.18.5 Ganlee Recent Developments
8 Industry Chain Analysis
8.1 Generic and Biosimilar Pharmaceuticals Industrial Chain
8.2 Generic and Biosimilar Pharmaceuticals Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Generic and Biosimilar Pharmaceuticals Sales Model
8.5.2 Sales Channel
8.5.3 Generic and Biosimilar Pharmaceuticals Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.